TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz), is a rapidly growing biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs with its unique expertise and infrastructure.
Mainz, Germany, May 2, 2012 – With more than 20 scientific abstracts TRON scientist present their latest research at the 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), May 14-16, 2013 in Mainz, Germany. Four abstracts will be presented as short talks. CIMT is the largest European meeting focused on cancer immunotherapy research and development.
Mainz, April 11, 2013 - "Induction of regulatory T cells by soluble CD83 - Modulation of the immune system in autoimmunity and transplantation"
with Prof. Dr. Alexander Steinkasserer, Head of Dept. of Immune Modulation at the Dept. of Dermatology, Erlangen, Germany
Mainz, March, 2013 -
Delegates from the Kurume University Department of Immunotherapy and the “Kurume Research Park” of Kurume City, Japan, have visited TRON to join forces in promoting concepts for personalized cancer medicine.